Strategic acquisition Recent acquisition by Ampersand Capital Partners and leadership hires signal capital backing, growth acceleration, and an expanded platform to pursue larger scale CDMO collaborations, presenting an opportunity to position Purna for broader outsourcing deals with multinational pharma companies and new biotech clients.

Global partner network Purna has established a reputation as a preferred partner for top-10 pharma multinationals and maintains a global presence. This offers a sales angle to target global active accounts seeking reliable out-sourcing for semi-solid, powders, and liquid dosage forms and to expand into new regional markets.

Integrated services By offering development and manufacturing services across semi-solid, powder, and liquid forms, plus R&D and an innovation network for out-licensing opportunities, Purna can cross-sell end-to-end CDMO services to emerging drug developers and small biotech aiming to de-risk and expedite pipelines.

Transatlantic collaboration Partnership with MedPharm to establish trans-Atlantic capabilities positions Purna to support global clients with faster time-to-market and regulatory alignment, creating sales opportunities among companies seeking cross-border manufacturing and regulatory expertise.

Public tender & access Exporting products via tender business to NGOs and national authorities indicates experience in price-competitive, high-volume supply. This can be leveraged to target contract opportunities with government programs, humanitarian channels, and volume-driven demand in emerging markets.